We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Imago BioSciences Inc | NASDAQ:IMGO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 36.01 | 37.82 | 34.21 | 0 | 00:00:00 |
By Colin Kellaher
Merck & Co. on Monday said it agreed to buy clinical-stage biopharmaceutical company Imago BioSciences Inc. in a $1.35 billion cash deal that bolsters Merck's hematology portfolio.
Kenilworth, N.J., drugmaker Merck said it would pay $36 a share for Imago, more than double Friday's closing price of $17.40 for the South San Francisco, Calif., company.
Imago is a developing new medicines for the treatment of myeloproliferative neoplasms and other bone-marrow diseases. The company's lead product candidate, bomedemstat, is in multiple Phase 2 studies for the treatment of essential thrombocythemia, myelofibrosis and polycythemia vera.
Merck said it expects to complete the acquisition of Imago in the first quarter of 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 21, 2022 07:14 ET (12:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Imago BioSciences Chart |
1 Month Imago BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions